NPI: 1346519816 · TAMPA, FL 33607 · General Acute Care Hospital · NPI assigned 12/29/2011
Authorized official GORKEN, LYNDA controls 20+ related entities in our dataset. Read more
| Authorized Official | GORKEN, LYNDA (VP, PATIENT FINANCIAL SERVICES) |
| Parent Organization | ST. JOSEPH'S HOSPITAL, INC. |
| NPI Enumeration Date | 12/29/2011 |
Other providers sharing the same authorized official: GORKEN, LYNDA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 1,913 | $61K |
| 2019 | 27,290 | $1.60M |
| 2020 | 18,249 | $976K |
| 2021 | 15,264 | $836K |
| 2022 | 11,829 | $671K |
| 2023 | 3,565 | $421K |
| 2024 | 748 | $141K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 8,937 | 7,524 | $1.08M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 2,606 | 2,288 | $634K |
| 59899 | 7,679 | 5,821 | $458K | |
| 81003 | 5,836 | 4,906 | $400K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 4,843 | 4,450 | $282K |
| 80053 | Comprehensive metabolic panel | 2,334 | 1,890 | $281K |
| 59025 | Fetal non-stress test | 2,227 | 1,077 | $253K |
| 84112 | 565 | 506 | $163K | |
| 76819 | Fetal biophysical profile; without non-stress testing | 1,515 | 891 | $159K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 2,196 | 2,073 | $123K |
| 36415 | Collection of venous blood by venipuncture | 3,721 | 2,851 | $112K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 864 | 762 | $107K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1,295 | 1,233 | $77K |
| 87480 | 1,461 | 1,338 | $75K | |
| 84702 | 1,737 | 1,212 | $69K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1,606 | 1,282 | $58K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 2,512 | 1,996 | $50K |
| 76825 | 166 | 153 | $39K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 1,379 | 1,165 | $37K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 405 | 365 | $32K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 304 | 266 | $28K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 694 | 638 | $25K |
| 82731 | 79 | 74 | $24K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1,248 | 1,058 | $23K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 222 | 184 | $15K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 384 | 351 | $15K |
| 86850 | 1,367 | 1,188 | $12K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 580 | 490 | $10K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 523 | 483 | $9K |
| 86900 | 1,594 | 1,383 | $8K | |
| 76801 | 1,681 | 1,314 | $8K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 65 | 64 | $6K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3,744 | 3,083 | $5K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 28 | 26 | $4K |
| G0378 | Hospital observation service, per hour | 1,146 | 502 | $4K |
| 84156 | 476 | 358 | $4K | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | 47 | 43 | $3K |
| 93325 | 143 | 133 | $3K | |
| 82948 | 89 | 52 | $2K | |
| 77066 | Tomosynthesis, mammo | 58 | 42 | $1K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 42 | 42 | $852.43 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 33 | 24 | $842.24 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1,536 | 1,127 | $783.70 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 192 | 146 | $767.90 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 211 | 164 | $765.44 |
| 86901 | 1,594 | 1,383 | $753.76 | |
| 76642 | 17 | 12 | $633.05 | |
| 87660 | 1,465 | 1,342 | $579.85 | |
| 77080 | 35 | 26 | $532.80 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 157 | 119 | $472.03 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 67 | 61 | $347.95 |
| 76827 | 129 | 121 | $330.47 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 373 | 301 | $306.58 |
| 87510 | 1,461 | 1,338 | $274.24 | |
| 76820 | 110 | 49 | $225.80 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 384 | 351 | $75.32 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 790 | 656 | $46.58 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 50 | 41 | $30.15 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 215 | 160 | $6.33 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 598 | 480 | $5.97 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 118 | 104 | $2.40 |
| 82570 | 400 | 334 | $1.74 | |
| 84550 | 128 | 102 | $0.87 | |
| 85027 | 19 | 12 | $0.62 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 39 | 24 | $0.60 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 29 | 25 | $0.31 |
| 87077 | 16 | 15 | $0.31 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 65 | 64 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 15 | 13 | $0.00 |
| 0352U | 67 | 60 | $0.00 | |
| 96375 | Therapeutic injection; each additional sequential IV push | 44 | 27 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 21 | 13 | $0.00 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 15 | 15 | $0.00 |
| 86780 | 12 | 12 | $0.00 | |
| 0353U | 14 | 12 | $0.00 | |
| 0100U | 14 | 12 | $0.00 | |
| 77065 | Tomosynthesis, mammo | 13 | 12 | $0.00 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 14 | 13 | $0.00 |